Qiagen N.V. $QGEN Shares Newly Purchased by Generali Asset Management SPA SGR

Key Points

• Generali Asset Management purchased 53,358 Qiagen shares worth approximately $2.34 million in the third quarter. Institutional investors collectively own 70% of the company.
• Qiagen reported quarterly EPS of $0.62, exceeding estimates of $0.60, while revenue reached $535.04 million, slightly above forecasts and up 0.2% year over year.
• Analyst sentiment remains cautious: Qiagen has an average “Hold” rating, with 11 holds and four buys, and an average price target of $46.09 versus the stock’s reported $50.38 price.

Generali Asset Management SPA SGR purchased a new stake in shares of Qiagen N.V. (NYSE:QGEN - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 53,358 shares of the company's stock, valued at approximately $2,335,000.

Several other institutional investors have also recently made changes to their positions in the business. Amundi lifted its stake in shares of Qiagen by 12.4% in the 1st quarter. Amundi now owns 4,757,681 shares of the company's stock worth $190,498,000 after purchasing an additional 524,959 shares during the period. State Street Corp boosted its holdings in shares of Qiagen by 4.5% in the second quarter. State Street Corp now owns 2,183,206 shares of the company's stock worth $85,363,000 after buying an additional 93,575 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Qiagen by 20.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company's stock valued at $66,649,000 after buying an additional 286,665 shares during the period. Swiss National Bank grew its position in Qiagen by 21.1% during the first quarter. Swiss National Bank now owns 716,059 shares of the company's stock valued at $28,686,000 after buying an additional 124,920 shares during the period. Finally, Arbejdsmarkedets Tillaegspension grew its position in Qiagen by 24.8% during the first quarter. Arbejdsmarkedets Tillaegspension now owns 636,918 shares of the company's stock valued at $25,502,000 after buying an additional 126,405 shares during the period. Institutional investors own 70.00% of the company's stock.

Qiagen Trading Up 0.1%

Shares of QGEN stock opened at $50.38 on Friday. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The stock's 50-day moving average price is $45.01 and its 200-day moving average price is $42.72. The stock has a market capitalization of $10.38 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 5.00 and a beta of 0.61.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The company had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. During the same period in the prior year, the company earned $0.60 earnings per share. The firm's revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts predict that Qiagen N.V. will post 2.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on QGEN. DZ Bank cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Thursday, October 22nd. Citigroup reiterated a "neutral" rating and set a $52.00 price target (up from $45.00) on shares of Qiagen in a research note on Monday. Jefferies Financial Group reissued a "buy" rating and set a $48.00 price objective on shares of Qiagen in a research report on Thursday, August 6th. Weiss Ratings upgraded Qiagen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 11th. Finally, JPMorgan Chase & Co. lowered Qiagen from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $55.00 to $52.00 in a research note on Thursday, October 22nd. Four analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $46.09.

Qiagen Profile

QIAGEN N.V. NYSE: QGEN is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.